Upon 18-h gefitinib treatment, Rab7 notably aggregated in cytosol in TKI-sensitive NSCLC cells but it showed consistently perinuclear localizations in TKI-resistant NSCLC cells (Fig. 5A). Here, RAB7A is linked to non-small cell lung carcinoma.